Skip to Content

Ivosidenib Disease Interactions

There are 2 disease interactions with ivosidenib:


Ivosidenib (applies to ivosidenib) QTc interval prolongation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Long QT Syndrome, Congestive Heart Failure, Magnesium Imbalance, Hypokalemia

Patients treated with ivosidenib can develop QTc prolongation and ventricular arrhythmias. Concomitant use of ivosidenib with drugs known to prolong the QTc interval (e.g., antiarrhythmic medicines, fluoroquinolones, triazole antifungals, 5-HT3 receptor antagonists) and CYP3A4 inhibitors may increase the risk of QTc interval prolongation. Conduct monitoring of electrocardiograms (ECGs) and electrolytes. In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent monitoring may be necessary. Treatment should be interrupted or dose reduced if QTc increases to greater than 480 msec. Permanently discontinue ivosidenib in patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia.


Ivosidenib (applies to ivosidenib) renal/hepatic

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Liver Disease

The pharmacokinetics of ivosidenib in patients with severe renal impairment (eGFR <30 mL/min/1.73m2,), renal impairment requiring dialysis, moderate hepatic impairment (total bilirubin 1.5 to 3.0 times the ULN and any value for AST), or severe hepatic impairment (total bilirubin greater than 3.0 times the ULN and any value for AST) is unknown. Caution is advised if using in these patients.

Ivosidenib drug interactions

There are 414 drug interactions with ivosidenib

Ivosidenib alcohol/food interactions

There is 1 alcohol/food interaction with ivosidenib

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.